The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Ide-cel (formerly bb2121) anti-BCMA CAR T-cell therapy in relapsed/refractory MM
Nikhil Munshi, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, USA, talks to us about the exciting results from his team’s Phase I study of idecabtagene vicleucel (formerly bb2121) anti-BCMA CAR T-cell therapy in adults with relapsed/refractory multiple myeloma (MM) (NCT02658929). As detailed by Dr. Munshi, his team observed durable and high rates of responses in patients and although there were toxicities, particularly in cytokine release, these were relatively controlled in comparison to that seen in other diseases. Overall, it appears that targeting BCMA through CAR T-cell therapy may represent a promising treatment for MM. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
